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1,25-Dihydroxyvitamin D3 negatively regulates the
renin–angiotensin system (RAS), which plays a critical role in
the development of diabetic nephropathy. We tested if mice
lacking the vitamin D receptor (VDR) are more susceptible to
hyperglycemia-induced renal injury. Diabetic VDR knockout
mice developed more severe albuminuria and
glomerulosclerosis due to increased glomerular basement
membrane thickening and podocyte effacement. More
fibronectin (FN) and less nephrin were expressed in the VDR
knockout mice compared to diabetic wild-type mice. In
receptor knockout mice, increased renin, angiotensinogen,
transforming growth factor-b (TGF-b), and connective tissue
growth factor accompanied the more severe renal injury.
1,25-Dihydroxyvitmain D3 inhibited high glucose (HG)-
induced FN production in cultured mesangial cells and
increased nephrin expression in cultured podocytes. 1,25-
Dihydroxyvitmain D3 also suppressed HG-induced activation
of the RAS and TGF-b in mesangial and juxtaglomerular cells.
Our study suggests that receptor-mediated vitamin D actions
are renoprotective in diabetic nephropathy.
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In both type I and type II diabetic mellitus, diabetic
nephropathy is the most common renal complication that
often leads to end-stage kidney disease with its attendant
renal failure and high mortality.1 Diabetic nephropathy is a
long-term complication, characterized initially by glomerular
and tubuloepithelial hypertrophy, and thickening of glomer-
ular and tubular basement membranes, followed by
hyperfiltration, albuminuria, glomerulosclerosis, and tubu-
lointerstitial fibrosis, leading eventually to end-stage kidney
disease.2 The pathogenesis of diabetic nephropathy is
complex and involves direct actions of extracellular glucose
on glomerular, tubular, vascular, and interstitial cells. These
actions lead to the stimulation of cytokines and growth
factors, such as angiotensin II (Ang II), transforming growth
factor-b (TGF-b), and monocyte chemoattractant protein
(MCP)-1, which play a major role in the development of
diabetic nephropathy.3–5
The renin–angiotensin system (RAS) has been implicated
as a major mediator of progressive renal injury in diabetic
nephropathy. Clinical studies demonstrated that treatment
with angiotensin-converting enzyme inhibitors or Ang II type
1 receptor blockers can reduce the progression of glomerulo-
sclerosis, tubulointerstitial fibrosis, and proteinuria.6–10
Because the systemic components of the RAS are actually
downregulated in diabetic mellitus,11 whereas renal inter-
stitial Ang II levels are 1000-fold higher than in the plasma,12
intrarenal RAS is believed to play the major damaging role.
Indeed, all components of the RAS are present within the
kidney.13 Kidney cells synthesize renin, renin receptor,14
angiotensinogen, and Ang II receptors independent of the
systemic RAS,15 making the kidney capable of maintaining
high intrarenal Ang II levels. In fact, intrarenal renin and
angiotensinogen levels are increased in diabetic animals,16,17
and high glucose (HG) is known to stimulate renin and Ang
II synthesis in mesangial cells (MCs).18,19 Intrarenal Ang II
has multiple effects that can contribute to the progression
of renal injury, such as increasing glomerular capillary
pressure and permeability (leading to proteinuria),
stimulation of renal cell proliferation and hypertrophy,
synthesis of cytokines and extracellular matrix (ECM) and
promotion of macrophage infiltration and inflammation.3,20
Consistent with a destructive role of the intrarenal RAS,
transgenic rats overexpressing renin with streptozotocin
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(STZ)-induced diabetes develop more severe diabetic
nephropathy.21
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the hormonal
form of vitamin D, is an endocrine hormone with multiple
physiological functions. We have demonstrated that
1,25(OH)2D3 functions as a negative endocrine regulator of
the RAS.22 1,25(OH)2D3 suppresses renin biosynthesis, and
null-mutant mice lacking the vitamin D receptor (VDR) gene
develop hyperreninemia, high blood pressure, and cardiac
hypertrophy.23–25 Low-calcemic vitamin D analogs are also
able to inhibit renin expression in animals.26 Given the
crucial role of the RAS in the development of diabetic
nephropathy, we speculate that vitamin D deficiency, which
can lead to activation of the RAS, may increase the
susceptibility to hyperglycemia-induced renal injury. Here
we show that VDR knockout mice develop more severe
diabetic nephropathy. Our data support the notion that
vitamin D plays a renoprotective role against renal injury by
regulation of the RAS and other genes involved in renal
injury.
RESULTS
We used VDR/ mice to test the hypothesis that vitamin D has
renoprotective activity and can ameliorate renal injury in
diabetic nephropathy. We reasoned that if vitamin D provides
renal protection, then mice lacking the VDR could be more
susceptible to hyperglycemia-induced renal injury. We used the
STZ-induced diabetes model, and followed the mice for up to 19
weeks. As shown in Figure 1, the blood glucose level rose to
around 450 mg dl1 in both VDRþ /þ and VDR/ mice 2
weeks after STZ treatment, and hyperglycemia persisted during
the 19-week period (Figure 1a); both VDRþ /þ and VDR/
mice exhibited a mild reduction of body weight during this time
(data not shown). As expected, both VDRþ /þ and VDR/
mice developed albuminuria (expressed as urinary albumin to
creatinine ratio (ACR)), and the severity increased with time
(Figure 1b). Remarkably, not only was the ACR significantly
higher in VDR/ mice compared to VDRþ /þ mice, but the
increase of ACR was also more robust in VDR/ mice, with
marked elevation seen at as early as 5–7 weeks after STZ
injection. Of note, non-diabetic VDR/ mice had similar blood
glucose levels as VDRþ /þ mice (81.578.4 vs 9778.2 mg dl1
at 7 months of age, n¼ 5). The urinary albumin levels were
similar in young non-diabetic VDRþ /þ and VDR/ mice, and
VDR/ mice tended to have higher urinary albumin excretion
than VDRþ /þ mice when aging (ACR: 216785 vs 169786 at 5
months of age, n¼ 4). Thus, diabetic VDR/ mice appeared to
develop earlier and more severe albuminuria compared to their
VDRþ /þ counterparts.
Histological examination of the kidney revealed that
diabetic VDR/ mice developed more severe glomerulo-
sclerosis than diabetic VDRþ /þ mice at week 19, manifested
by more ECM accumulation in the mesangium (Figure 2a).
In comparison, ECM accumulation in non-diabetic
VDRþ /þ and VDR/ mice was minimal (Figure 2a).
Semiquantitative scoring of the kidney sections confirmed
this observation (Figure 2b). Consistently, the expression of
fibronectin (FN), one of the major ECM proteins, was also
higher in VDR/ mice than in VDRþ /þ mice, as
determined by immunofluorescent staining (Figure 2c) and
western blotting (Figure 2d and e). We also measured the
protein level of podocin and nephrin in kidney lysates from
the two groups of mice by western blotting. Whereas the level
of podocin was similar, nephrin was significantly reduced in
VDR/ mice at week 19 (Figure 3a–c). This is consistent
with the more severe albuminuria phenotype observed in
VDR/ mice, as nephrin is a key component of the slit
diaphragm of the glomerular filtration barrier and plays a
critical role in the regulation of protein filtration.27
We further examined the kidney structure by electron
microscopy. As shown in Figure 4, normal morphology of the
glomerular filtration barrier including glomerular basement
membrane (GBM) and podocyte foot processes was seen in
non-diabetic VDRþ /þ and VDR/ mice (Figure 4a and b).
As expected, chronic diabetes caused an increase in GBM
thickness and foot process effacement. Interestingly, the
increase in GBM thickness and the extent of foot process
effacement were more remarkable and robust in diabetic
VDR/ mice (Figure 4d and e) than in VDRþ /þ mice
(Figure 4c and e). The impairment of the glomerular
filtration barrier is consistent with the more severe albumi-
nuria observed in VDR/ mice (Figure 1b).
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Figure 1 | Time-course changes of blood glucose and urinary
albumin in mice with STZ-induced diabetes. VDRþ /þ and VDR/
mice were injected intraperitoneally with 50 mg kg1 STZ for 5
consecutive days in the first week (week 0), and their blood glucose
and urinary albumin levels were monitored for up to 19 weeks.
(a) Fasting blood glucose levels and (b) urinary albumin to creatinine
ratio (ACR). Note VDR/ mice developed earlier and more severe
albuminuria. *Po0.05 vs VDRþ /þ control, n¼ 5–7 in each genotype.
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Renal cells are known to have all components of the RAS.
Hyperglycemia has been shown to stimulate the intrarenal
RAS, and high levels of Ang II can cause renal injury.3 Given
the important role of the intrarenal RAS in the development
of diabetic nephropathy, we quantified the expression of the
RAS genes in the kidney at week 19 by real-time reverse
transcriptase PCR (RT-PCR). As shown in Figure 5, hyper-
glycemia markedly induced the steady-state mRNA levels of
renin (44-fold, Figure 5a), angiotensinogen (46-fold,
Figure 5b), and Ang II type 1 receptor (AT1R, fourfold,
Figure 5c) in VDRþ /þ mice. The increase of the RAS in
VDR/ mice was more robust. As has been shown
previously,25 the basal level of renin in non-diabetic VDR/
mice was already upregulated. In diabetic VDR/ mice, the
renin mRNA level was further increased (Figure 5a), even
though the induction over the VDR/ baseline was similar
in comparison to VDRþ /þ mice. Similarly, angiotensinogen
and AT1R were also induced to a higher level in diabetic
VDR/ mice (Figure 5b and c). The more robust increase in
renin mRNA in the kidney of diabetic VDR/ mice was also
detected by northern blot analysis (Figure 5d). Moreover,
immunostaining of the kidney sections confirmed a more
robust induction at renin protein levels in the juxtaglomer-
ular apparatus of VDR/ mice (Figure 5e); AT1R protein
was also increased more in diabetic VDR/ mice than in
diabetic VDRþ /þ mice, mostly in the cytoplasm of tubular
epithelial cells (Figure 5f). Little staining was seen in the non-
diabetic mice. The level of ACE was not significantly altered
in diabetic mice (data not shown). Therefore, the enhanced
renal injury observed in diabetic VDR/ mice was
accompanied by an apparently higher degree of RAS
induction.
It has been implicated that TGF-b and connective tissue
growth factor (CTGF) play important roles in the develop-
ment of glomerular sclerosis;4,28 therefore, we also compared
the expression of TGF-b and CTGF in diabetic VDRþ /þ and
VDR/ mice by real-time RT-PCR analyses. There was a
modest increase in renal TGF-b mRNA expression in diabetic
mice compared with non-diabetic mice, with the induction
in diabetic VDR/ mice (50%) higher than in diabetic
VDRþ /þ mice (20%) (Figure 6a). Renal CTGF mRNA levels
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Figure 2 | Glomerulosclerosis in diabetic mice. VDRþ /þ and VDR/ mice were killed 19 weeks after STZ treatment, and the kidneys were
harvested for histological analyses. (a) Representative glomerular morphology of non-diabetic and diabetic VDRþ /þ and VDR/ mice, stained
with periodic acid-Schiff (PAS); (b) semiquantitative glomerulosclerotic scores of non-diabetic and diabetic VDRþ /þ and VDR/ mice,
determined from 20 to 30 glomeruli in each mouse. *Po0.05 vs VDRþ /þ , n¼ 4 in each group. (c) Immunostaining of kidney sections from
diabetic mice with anti-fibronectin (FN) antibody. (d) VDR and FN protein levels in kidney lysates of diabetic mice determined by western blot
analyses; (e) densitometric quantification of the FN protein levels. *Po0.05 vs VDRþ /þ , n¼ 3.
VDR(+/+)
VDR(+/+)VDR(+/+)
VDR(–/–)
VDR(–/–)VDR(–/–)
Po
do
cin
 p
ro
te
in
 le
ve
l
N
ep
hr
in
 p
ro
te
in
 le
ve
l
Nephrin
Podocin
β-Actin
β-Actin
1.4
1.2
0.8
0.6
0.4
0.2
0
1
1.4
1.2
0.8
0.6
0.4
0.2
0
1
*
Figure 3 | Expression of podocin and nephrin in diabetic mice.
(a) Western blot analyses of podocin and nephrin protein in kidney
lysates from STZ-treated VDRþ /þ and VDR/ mice at week 19.
Densitometric quantification of (b) podocin and (c) nephrin levels in
these mice. *Po0.05 vs VDRþ /þ , n¼ 3.
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were similarly induced over the baseline in diabetic VDRþ /þ
and VDR/ mice; however, the basal CTGF level was already
elevated in non-diabetic VDR/ mice, and hence, CTGF
expression was increased to a higher level in diabetic VDR/
mice than the VDRþ /þ counterparts (Figure 6b). These data
are consistent with the more severe glomerular phenotype in
the mutant mice.
The development of more severe glomerular abnormalities
in diabetic VDR/ mice suggests a protective role of vitamin
D against renal injury in diabetic nephropathy. To explore the
molecular basis, we utilized in vitro cell cultures to investigate
the effect of vitamin D. MCs are the major component of the
glomerular mesangium that provides structural support for
the glomerular capillary. Hyperglycemia-stimulated ECM
overproduction by MCs leads to glomerulosclerosis in
diabetic nephropathy.29 In MC cultures, HG (30 mM)
markedly induced FN expression at both the mRNA
and protein levels, and this stimulation was suppressed
by 1,25(OH)2D3 in a dose-dependent manner (Figure 7a).
As a result, FN synthesis was virtually normalized at
107 M. Immunostaining with anti-FN antibody confirmed
that 1,25(OH)2D3 blocked the HG-induced FN induction
(Figure 7b).
We also examined the effect of HG and vitamin D on the
RAS in cell cultures. As shown in Figure 8, a low level of renin
was detected in MCs by RT-PCR, which was increased by
approximately twofold by HG; the induction was blocked in
the presence of 1,25(OH)2D3 (Figure 8a). Similar results were
observed in As4.1 cells, a juxtaglomerular cell line expressing
a high level of renin, in which 1,25(OH)2D3 reversed the HG
induction of renin expression in a dose-dependent manner
(Figure 8e). HG also dramatically increased the expression of
angiotensinogen (by 45-fold) and AT1R (by 46-fold) in
MCs, and 1,25(OH)2D3 markedly inhibited the increase of
these gene expressions (Figure 8c and d). Consistent with the
animal data, no changes were seen in the expression of ACE
in the presence of HG or 1,25(OH)2D3 (Figure 8b).
In MCs, HG also induced TGF-b expression, and the
induction was partially suppressed by 1,25(OH)2D3 (Figure
9a). In podocytes, HG decreased nephrin expression by
approximately 25%, and 1,25(OH)2D3 dose dependently
stimulated nephrin mRNA expression (Figure 9b), suggesting
that nephrin may be a direct target of vitamin D regulation.
This is consistent with the in vivo data showing a lower
nephrin expression in diabetic VDR/ mice (Figure 3).
DISCUSSION
It is well established that the vitamin D endocrine system
functions beyond the regulation of calcium and phosphate
metabolism. Emerging clinical and animal studies have
revealed pivotal protective roles of vitamin D in the renal
and cardiovascular systems.30 Vitamin D/vitamin D analog
therapy offers significant survival advantage for patients with
chronic kidney disease, with improvement in renal and
cardiovascular functions.31–33 A recent clinical trial shows
that paricalcitol, an activated vitamin D analog, can reduce
proteinuria in chronic kidney disease patients.34 In subtotally
nephrectomized rats, administration of 1,25(OH)2D3 sig-
nificantly decreased albuminuria, podocyte hypertrophy, and
glomerulosclerosis.35 22-Oxacalcitriol, a low-calcemic vita-
min D analog, inhibited MC proliferation in vitro36 and
ameliorated glomerular injury in rats with glomerulone-
phritis.37 However, to our knowledge, the effect of vitamin D
on the development of diabetic nephropathy has not been
reported.
Our data obtained from this investigation are consistent
with the notion that vitamin D plays a renoprotective role
against renal injury in diabetic mice.38 In this study, we
demonstrated that mice lacking VDR develop more severe
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Figure 4 | Transmission electron microscopic examination of the
glomerular basement membrane (GBM). (a) Non-diabetic VDRþ /þ
mice; (b) non-diabetic VDR/ mice; (c) diabetic VDRþ /þ mice at
week 19; (d) diabetic VDR/ mice at week 19. Arrows indicate the
thickness of the GBM; arrowheads indicate foot process effacement.
(e) Quantification of the thickness of the GBM from these four types
of mice. *Po0.01 vs non-diabetic; **Po0.01 vs the rest.
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diabetic nephropathy compared to wild-type mice. The
pathological hallmarks of diabetic nephropathy include
proteinuria and glomerulosclerosis,2 and both are more
severe in diabetic VDR knockout mice. Despite similar levels
of hyperglycemia in wild-type and VDR knockout mice,
albuminuria was markedly more severe with an earlier onset
in VDR knockout mice compared to wild-type mice. This
finding is particularly interesting because it is consistent with
a recent clinical observation that vitamin D analog reduced
proteinuria in chronic kidney disease patients.34 Severe
albuminuria was accompanied by increased GBM thickness
and decreased nephrin expression in VDR knockout mice.
The effect of VDR ablation on podocytes is consistent with
an early study showing that vitamin D can prevent the loss of
podocytes and reduce podocyte injury in nephrectomized
rats.35 On the other hand, accumulation of mesangial
extracellular matrix is also more prominent in VDR knock-
out mice, with higher FN expression. These results suggest
that mice are more susceptible to hyperglycemia-induced
renal injury in the absence of VDR or in vitamin D
deficiency, supporting a protective role of VDR in diabetic
nephropathy.
Vitamin D has several important activities that may
contribute to its renoprotective property. These activities
include inhibition of profibrotic growth factors and inflam-
matory cytokines and suppression of the RAS. First,
1,25(OH)2D3 may target TGF-b and CTGF, known as
important mediators for the development of sclerosis in
diabetic nephropathy.4,28,39 1,25(OH)2D3 is known to down-
regulate TGF-b signaling by suppressing Smad3 expression in
N
on
-d
ia
be
tic
R
en
in
 m
R
N
A 
le
ve
l
AG
T 
m
RN
A 
lev
e
l
AT
1R
 m
R
N
A 
le
ve
l
D
ia
be
tic
N
on
-d
ia
be
tic
D
ia
be
tic
VDR(+/+)
VDR(+/+)
VDR(–/–) VDR(+/+) VDR(–/–)
VDR(–/–)
VDR(+/+) VDR(–/–)
VDR(+/+) VDR(–/–) VDR(+/+) VDR(–/–)
*
* *
*
*
*
**
*
**
12
10
4
2
0
C STZ
STZ STZ
Renin
36B4
Control Control
C STZ C STZ C STZ C STZ C STZ
8
6
12
10
4
2
0
8
6
12
14
10
4
2
0
8
6
Figure 5 | Activation of the RAS in the kidney of diabetic mice. Control (C) or STZ-treated VDRþ /þ and VDR/ mice were killed at week 19,
and kidneys were harvested immediately for total RNA isolation or for immunostaining analyses. The mRNA levels of (a) renin, (b)
angiotensinogen (AGT), (c) and Ang II type 1 receptor (AT1R) in the kidney were determined by real-time RT-PCR. *Po0.05 vs VDRþ /þ control;
**Po0.05 vs diabetic VDRþ /þ , n¼ 4–5. (d) Renin mRNA levels were further measured by northern blot. The kidney sections from the non-
diabetic and diabetic VDRþ /þ and VDR/ mice as indicated were stained with antibody against (e) renin or (f) AT1R. Arrows indicate renin-
positive juxtaglomerular (JG) cells or AT1R-positive tubular cells. Note the higher level of renin in the JG apparatus of diabetic VDR/ mice; also
note higher AT1R induction is in the tubular cells in diabetic VDR/ mice.
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renal tissue40 or by inducing VDR physical interaction with
Smad3 protein;41 therefore, VDR ablation may increase
Smad3 activity. This, in conjunction with the increase in
TGF-b levels, will lead to more active TGF-b signaling in
VDR/ mice. Vitamin D is likely a suppressor of CTGF
synthesis; higher CTGF levels also contribute to the
fibrogenic potential in diabetic VDR knockout mice. Most
recently we demonstrated that vitamin D also regulates MCP-1,
an inflammatory cytokine that stimulates macrophage
infiltration into the kidney, to ameliorate renal injury.42 In
addition, 1,25(OH)2D3 may also directly inhibit HG-induced
FN expression and stimulate nephrin expression.
Second, the renoprotective property of vitamin D may
also be attributed to its regulation of the RAS, particularly
renin.25 Intrarenal RAS is increased in diabetes and plays a
key role in development of diabetic nephropathy.3,16 Ang II
stimulates TGF-b expression and ECM protein production in
mesangial and tubular cells;43 Ang II also increases glomer-
ular permeability and induces glomerular injury leading to
proteinuria. Inhibition of renin activity or Ang II activity has
been reported to ameliorate diabetic nephropathy in animal
and humans.10,44 Our data show that renin, angiotensinogen,
and AT1R expressions in the kidney were increased in
diabetic mice. Importantly, the increased renal injury seen in
VDR knockout mice was accompanied by higher expression
of renal renin, angiotensinogen, and AT1R. The increase in
blood pressure in VDR/ mice due to RAS activation25 may
also contribute to the increased renal damage. Consistently,
in vitro studies showed that 1,25(OH)2D3 suppressed HG-
induced expression of renin as well as angiotensinogen
and AT1R. Recently, podocytes have also been shown to
increase the RAS activation under a HG condition.45,46 These
in vitro and in vivo data suggest that one important
mechanism by which vitamin D protects against renal injury
is by suppressing the activation of the RAS induced by
hyperglycemia.
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Figure 8 | Effect of vitamin D on RAS expression in MCs and JG
cells. (a–d) MCs were grown in media containing 5 mM (LG) or 30 mM
glucose (HG) in the presence or absence of 108 M 1,25(OH)2D3
(þVD) as indicated for 24 h. Total RNAs were extracted and the level
of (a) renin, (b) angiotensin-converting enzyme (ACE), (c)
angiotensinogen (AGT), (d) and AT1 receptor (AT1R) were
determined by real-time RT-PCR. Note the stimulation of renin, AT1
receptor, and angiotensinogen was blocked by 1,25(OH)2D3. *Po0.05
vs LG; **Po0.05 vs HG. (e) As4.1 cells were cultured for 24 h in the
medium containing 5 or 30 mM glucose in the presence or absence of
different concentrations of 1,25(OH)2D3 as indicated. Renin mRNA
expression was determined by northern blotting.
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The renin/prorenin receptor identified recently is highly
expressed in MCs and vascular smooth muscle cells.14
Activation of this membrane receptor by the renin/prorenin
peptide has been shown to stimulate TGF-b in MCs47 and
cause renal injury independent of Ang II.48 Inhibition of
prorenin activity has been shown to block diabetic nephro-
pathy development.44,49 Therefore, the fact that diabetic
VDR/ mice have much higher renin induction under
diabetic condition is probably the key to explain the more
severe phenotype in these mutant mice, because the highly
stimulated renin/prorenin concentration in the kidney can
cause Ang II-dependent and -independent renal injury. In
this regard, it is interesting to note that the proteinuria and
glomerulosclerosis phenotypes of VDR/ mice are similar to
those of human prorenin receptor transgenic mice reported
recently.50 Studies using inhibitors to block renin or Ang II
are underway to confirm the RAS-dependent phenotypes in
diabetic VDR/ mice.
The data presented in this report suggest that VDR is an
important mediator in renal protection. As a ligand-activated
transcription factor, it is not surprising that VDR may target
multiple pathways or factors to result in a renoprotective
action. However, some regulation may be indirect. For
example, vitamin D can regulate TGF-b and ECM protein
synthesis by targeting the RAS, as Ang II regulates these
genes. In this regard, the primary mechanism involved in
vitamin D’s protective action against renal injury remains to
be further defined.
In the last decades, the synthesis of vitamin D analogs with
similar VDR-activating property but lower calcemic activity
has offered new compounds with a wider therapeutic window
and less hypercalcemic side effect than 1,25(OH)2D3 in
clinical applications.51 Given the renoprotective property of
VDR as evidenced in this and other previous investiga-
tions,34,37,42 it is worthwhile to explore further the ther-
apeutic potential of vitamin D analogs in the prevention and
intervention of diabetic nephropathy in the future.
MATERIALS AND METHODS
Animal studies
Two-month-old male C57BL/6 VDRþ /þ and VDR/ mice52 were
used in this study. The mice were injected intraperitoneally with
freshly prepared STZ (dissolved in 10 mM citrate buffer, pH 4.2) at
50 mg kg1 for 5 consecutive days. Blood glucose levels were
monitored with One-Touch Glucometer (Lifescan, Milpitas, CA,
USA) by using one drop of tail blood. Spot urine was collected
biweekly or monthly, and urinary albumin and creatinine levels were
determined using commercial kits (albumin: Bethyl Laboratory,
Montgomery, TX, USA; creatinine: Exocell, Philadelphia, PA, USA).
All mice were killed at 19 weeks after the start of STZ treatment, and
kidneys were immediately harvested for protein or RNA extraction
or for histological analyses. The animal study protocol was approved
by the Institutional Animal Care and Use Committee at The
University of Chicago.
Renal histology and immunohistochemistry
Freshly dissected kidneys were fixed overnight with 4% formalde-
hyde in phosphate-buffered saline (pH 7.2), processed, embedded in
paraffin, and cut into 4-mm sections with Leica Microtome 2030.
Renal sections were stained with hematoxylin and eosin or with
periodic acid-Schiff according to standard procedures. Semiquanti-
tative scoring of glomerular sclerosis in periodic acid-Schiff-stained
slides was performed using a five-grade method described
previously.53 The scoring was blinded and at least 20–30 glomeruli
per mouse were scored from 4 to 5 mice in each group. Section
immunostaining was performed using primary antibody against
renin or AT1R (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Antigen signals were detected with peroxidase-conjugated secondary
antibody and visualized with a 3,30-diaminobenzidine peroxidase
substrate kit (Vector Lab, Burlingame, CA, USA) or by incubation
with fluorescein isothiocyanate-conjugated secondary antibody.
Electron microscopy
Kidney cortex was fixed in 2% glutaraldehyde and post-fixed in
osmium tetroxide in 1% in 0.1 M phosphate buffer, pH 7.4 for 1 h at
room temperature. The tissues were dehydrated in an ascending
series of ethanol and infiltrated with Eponate 12 resin (Ted Pella,
Redding, CA, USA), and then embedded and polymerized at 701C
for 24 h. Resin-embedded blocks were sectioned at 70 nm and
collected on 200-mesh, Formvar-coated copper grids. Grids were
stained with uranyl acetate and lead citrate and examined with a
JEOL 1200 EX II transmission electron microscope. GBM thickness
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Figure 9 | Effect of vitamin D on TGF-b and nephrin expression in
cell cultures. (a) TGF-b expression in MCs. MCs were cultured in
media containing 5 (LG) or 30 mM (HG) in the presence of 108 M
1,25(OH)2D3 (þVD) for 24 h. (b) Nephrin expression in podocytes.
Podocytes were grown in media containing 5 or 30 mM glucose in the
presence or absence of different doses of 1,25(OH)2D3 as indicated.
The levels of nephrin and TGF-b mRNA transcripts were determined
by real-time RT-PCR. *Po0.05 vs 5 mM glucose or LG; **Po0.05 vs HG.
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was determined as described previously.54 Briefly, electron micro-
scopic pictures were taken with the same magnification and
converted to Adobe PDF file. The distance between the endothelial
cell and epithelial cell plasma membranes was measured with the
ruler in Adobe PDF file at more than 50 sites, and the mean value of
these measurements was used to calculate the GBM thickness based
on the magnification value.Cell culture
Mouse MCs (ATCC, Manassas, VA, USA) were routinely
maintained in Dulbecco’s modified Eagle’s medium/F12 (containing
B10 mM glucose) supplemented with 10% heat-inactivated fetal
bovine serum in 5% CO2 incubator at 371C. Podocytes (kindly
provided by Dr Peter Mundel, Mount Sinai Medical College, New
York, USA)55 were grown to 80% confluence in collagen-coated
flasks at the permissive temperature (331C) in RPMI-1640
supplemented with 10% fetal bovine serum and 50 U/ml g-
interferon. The cells were then subcultured at 371C without g-
interferon (non-permissive condition). For HG stimulation, the cells
were first synchronized in serum-free Dulbecco’s modified Eagle’s
medium for 48 h at 371C, and then changed to 5 mM glucose
Dulbecco’s modified Eagle’s medium–10% fetal bovine serum (low
glucose media) or 30 mM glucose Dulbecco’s modified Eagle’s
medium–10% fetal bovine serum (HG media) and cultured for
24–48 h in the presence or absence of 1,25(OH)2D3. The treated cells
were used to extract total RNAs or cell lysates for northern, western
blot, or real-time RT-PCR analyses.
Western blot
Western blot analyses were performed as described previously.56
Protein lysates were separated by sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis and electroblotted onto Immobilon-P
membranes. The membrane blots were probed with primary and
secondary antibodies. Antibodies against FN and actin were from
Sigma (St Louis, MO, USA), and antibodies against podocin and
nephrin were kindly provided by Dr Lawrence Holzman (University
of Michigan). The antigens were visualized using the ECL System
from Amersham (Piscataway, NJ, USA).
Northern blot
Total RNAs were isolated using TRIzol reagents (Invitrogen, Grand
Island, NY). Total RNAs were separated on 0.8% agarose gels
containing 0.6 M formaldehyde, transferred onto a Nylon membrane,
and cross-linked in an ultraviolet cross-linker. Hybridization was
carried out at 651C in the Church and Gilbert57 buffer with a cDNA
probe labeled with 32P-dATP using the Prime-a-Gene Labeling
System (Promega, Madison, WI, USA). Autoradiography was
obtained by exposing the membrane to X-ray films at 801C. The
relative amount of mRNA was normalized with 36B4 mRNA.
Real-time RT-PCR
First-strand cDNAs were synthesized from 4 mg of total RNAs in
20 ml reaction using MML-V reverse transcriptase (Invitrogen) and
hexanucleotide random primers. Real-time PCR was performed in
an Applied Biosystems 7300 Real-Time PCR System using a SYBR
green PCR reagent kit (Applied Biosystems, Foster City, CA, USA).
The change in mRNA levels was determined based on the formula
2 DDCtð Þ, where DCt is the value from the threshold cycle (Ct) value
of the treated sample subtracting the Ct value of the untreated or
zero time-point control sample. The relative amount of the sample
mRNA was normalized to the b2-microglobulin mRNA. The PCR
primers used in this study are listed in Table 1.
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